

# Pedro Coelho Barata

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6649636/publications.pdf>

Version: 2024-02-01

165  
papers

2,481  
citations

361296

20  
h-index

265120

42  
g-index

167  
all docs

167  
docs citations

167  
times ranked

3683  
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment of renal cell carcinoma: Current status and future directions. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 507-524.	157.7	583
2	Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. , 2018, 6, 9.		141
3	RNA-targeted therapeutics in cancer clinical trials: Current status and future directions. <i>Cancer Treatment Reviews</i> , 2016, 50, 35-47.	3.4	128
4	A Case of Post-Radiotherapy Gastritis: Radiation Does Not Explain Everything. <i>Case Reports in Oncology</i> , 2015, 8, 9-14.	0.3	107
5	Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. <i>Cancer</i> , 2018, 124, 2115-2124.	2.0	79
6	PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy. <i>Cancers</i> , 2020, 12, 1367.	1.7	75
7	Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 1208-1216.	2.0	70
8	Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA. , 2020, 8, e001065.		70
9	Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance. <i>Annals of Oncology</i> , 2017, 28, 2458-2463.	0.6	68
10	Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab. , 2018, 6, 107.		52
11	Metastatic castration-sensitive prostate cancer: Abiraterone, docetaxel, or enzalutamide. <i>Cancer</i> , 2019, 125, 1777-1788.	2.0	50
12	Physical and Chemical Stimuli-Responsive Drug Delivery Systems: Targeted Delivery and Main Routes of Administration. <i>Current Pharmaceutical Design</i> , 2013, 19, 7169-7184.	0.9	50
13	Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. <i>Journal of the National Cancer Institute</i> , 2019, 111, 118-128.	3.0	49
14	Outcomes and satisfaction of two optional cadaveric dissection courses: A 3-year prospective study. <i>Anatomical Sciences Education</i> , 2017, 10, 127-136.	2.5	44
15	The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 160-163.	2.9	39
16	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021, 4, 464-472.	2.6	39
17	Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1623-1630.	3.2	33
18	Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. <i>Journal of Urology</i> , 2020, 204, 63-70.	0.2	32

#	ARTICLE	IF	CITATIONS
19	Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study. <i>European Urology Oncology</i> , 2020, 3, 695-699.	2.6	30
20	Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. <i>Prostate</i> , 2021, 81, 433-439.	1.2	29
21	Comprehensive Analysis of <i>AR</i> Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer. <i>Oncologist</i> , 2020, 25, 327-333.	1.9	27
22	Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. <i>Oncotarget</i> , 2018, 9, 33232-33243.	0.8	26
23	Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. <i>Cancer</i> , 2022, 128, 1194-1205.	2.0	26
24	Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e879-e892.	0.9	25
25	A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC). <i>Investigational New Drugs</i> , 2018, 36, 451-457.	1.2	24
26	Repurposing ketoconazole as an exosome directed adjunct to sunitinib in treating renal cell carcinoma. <i>Scientific Reports</i> , 2021, 11, 10200.	1.6	23
27	Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma. <i>Targeted Oncology</i> , 2018, 13, 599-609.	1.7	22
28	Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer. <i>Investigational New Drugs</i> , 2019, 37, 1231-1238.	1.2	22
29	Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 413-419.e1.	0.9	21
30	Improving attribution of adverse events in oncology clinical trials. <i>Cancer Treatment Reviews</i> , 2019, 76, 33-40.	3.4	19
31	Phase I/II study evaluating the safety and clinical efficacy of tamsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer. <i>Investigational New Drugs</i> , 2019, 37, 331-337.	1.2	18
32	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. <i>BJU International</i> , 2021, 128, 196-205.	1.3	18
33	Symptom clusters and survival in Portuguese patients with advanced cancer. <i>Cancer Medicine</i> , 2016, 5, 2731-2739.	1.3	17
34	Differential Activity of PARP Inhibitors in <i>BRCA1</i> - Versus <i>BRCA2</i> -Altered Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 1200-1220.	1.5	17
35	Seizure frequency in more than 180,000 treatment sessions with hyperbaric oxygen therapy â€” a single centre 20-year analysis. <i>Diving and Hyperbaric Medicine</i> , 2019, 49, 167-174.	0.2	17
36	PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 388-396.	2.0	15

#	ARTICLE	IF	CITATIONS
37	Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 425-433.	0.9	15
38	Combination of Tipifarnib and Sunitinib Overcomes Renal Cell Carcinoma Resistance to Tyrosine Kinase Inhibitors via Tumor-Derived Exosome and T Cell Modulation. <i>Cancers</i> , 2022, 14, 903.	1.7	15
39	Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies. <i>Targeted Oncology</i> , 2018, 13, 353-361.	1.7	14
40	Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2020, 12, 3467.	1.7	13
41	Update on First-Line Combination Treatment Approaches in Metastatic Clear-Cell Renal Cell Carcinoma. Current Treatment Options in Oncology, 2021, 22, 15.	1.3	13
42	Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?. <i>Cancers</i> , 2021, 13, 5065.	1.7	13
43	Targeted Next-Generation Sequencing in Men with Metastatic Prostate Cancer: a Pilot Study. <i>Targeted Oncology</i> , 2018, 13, 495-500.	1.7	12
44	Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer. <i>Investigational New Drugs</i> , 2019, 37, 559-566.	1.2	12
45	Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy. <i>Prostate</i> , 2018, 78, 1035-1041.	1.2	11
46	Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort. <i>Frontiers in Oncology</i> , 2020, 10, 581189.	1.3	11
47	Nivolumab treatment for patients with non-clear cell renal cell carcinoma: A multicenter retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4586-4586.	0.8	10
48	Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e440-e452.	0.9	10
49	Blood-based tumor mutational burden from circulating tumor DNA (ctDNA) across advanced solid malignancies using a commercially available liquid biopsy assay.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3040-3040.	0.8	9
50	Evaluation of the genomic alterations in the androgen receptor gene during treatment with high-dose testosterone for metastatic castrate-resistant prostate cancer. <i>Oncotarget</i> , 2020, 11, 15-21.	0.8	9
51	Immunological correlates of response to immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2018, 36, 454-454.	0.8	9
52	Breast Cancer Presents with a Paraneoplastic Neurologic Syndrome. <i>Case Reports in Oncology</i> , 2012, 5, 616-621.	0.3	8
53	Evaluation of Response to Enzalutamide Consecutively After Abiraterone Acetate/Prednisone Failure in Patients With Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 429-436.	0.9	8
54	&lt;p&gt;Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 7253-7262.	0.9	8

#	ARTICLE	IF	CITATIONS
55	Circulating tumor (ct)-DNA alterations in advanced urothelial carcinoma: Association with outcomes and evolution with therapy.. Journal of Clinical Oncology, 2017, 35, 334-334.	0.8	8
56	TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2020, 18, 148-154.	0.9	7
57	Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients. Prostate, 2021, 81, 427-432.	1.2	7
58	Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study. Investigational New Drugs, 2018, 36, 1085-1092.	1.2	6
59	Implications of the United States Preventive Services Task Force Recommendations on Prostate Cancer Stage Migration. Clinical Genitourinary Cancer, 2021, 19, e12-e16.	0.9	6
60	Clinical outcome of patients (Pts) with metastatic renal cell carcinoma (mRCC) progressing on front-line immune-oncology based combination (IO-COMBO) regimens.. Journal of Clinical Oncology, 2018, 36, 613-613.	0.8	6
61	Pazopanib-Induced Cutaneous Leukocytoclastic Vasculitis: An Exclusion Diagnosis of a Multidisciplinary Approach. Case Reports in Oncology, 2018, 10, 1041-1049.	0.3	5
62	Relationship between serum markers and volume of liver metastases in castration-resistant prostate cancer. Cancer Treatment and Research Communications, 2019, 20, 100151.	0.7	5
63	Artificial Intelligence in Cancer Care: Legal and Regulatory Dimensions. Oncologist, 2021, 26, 807-810.	1.9	5
64	Continuous infusion 5-fluorouracil (5FU) as a novel treatment for heavily pretreated prostate cancer patients: An update.. Journal of Clinical Oncology, 2019, 37, 319-319.	0.8	5
65	Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer. Oncologist, 2022, 27, 220-227.	1.9	5
66	Precision therapy in advanced urothelial cancer. Expert Review of Precision Medicine and Drug Development, 2019, 4, 81-93.	0.4	4
67	Identifying Prostate Surface Antigen Patterns of Change in Patients with Metastatic Hormone Sensitive Prostate Cancer Treated with Abiraterone and Prednisone. Targeted Oncology, 2020, 15, 477-483.	1.7	4
68	Non-metastatic castration-resistant prostate cancer: current status and future directions. Expert Review of Anticancer Therapy, 2020, 20, 513-522.	1.1	4
69	Efficacy of enfortumab vedotin in advanced urothelial cancer: Retrospective analysis of the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) Study.. Journal of Clinical Oncology, 2021, 39, 443-443.	0.8	4
70	Differential activity of PARP inhibitors in <i>BRCA1</i>- versus <i>BRCA2</i>-altered metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, 100-100.	0.8	4
71	Change in neutrophil to lymphocyte ratio (NLR) as a predictor of treatment failure in renal cell carcinoma patients: Analysis of the IROC (Investigating RCC Outcomes) cohort.. Journal of Clinical Oncology, 2021, 39, 344-344.	0.8	4
72	Intra-patient heterogeneity in urothelial cancer (UC) circulating tumor cells (CTC) and PDL1 expression to identify biomarkers of response and new therapeutic targets: A pilot study.. Journal of Clinical Oncology, 2017, 35, 4537-4537.	0.8	4

#	ARTICLE	IF	CITATIONS
73	Clinicopathologic factors, treatment patterns, and outcomes in micropapillary urothelial carcinoma (UC).. Journal of Clinical Oncology, 2018, 36, 439-439.	0.8	4
74	Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. Clinical Genitourinary Cancer, 2022, 20, 165-175.	0.9	4
75	Stimuli-responsive nanosystems for drug-targeted delivery. , 2018, , 155-209.		3
76	Long-term Disease Control Using Taxane/Platinum-based Chemotherapy in CDK12-mutated Advanced Prostate Cancer. Oncologist, 2020, 25, e1421-e1422.	1.9	3
77	The addition of apalutamide to ADT in the treatment of metastatic castration-sensitive prostate cancer: safety and efficacy. Expert Review of Anticancer Therapy, 2020, 20, 147-150.	1.1	3
78	Outlook into the future of front-line immune checkpoint inhibition in metastatic urothelial carcinoma. Therapeutic Advances in Urology, 2021, 13, 175628722110047.	0.9	3
79	The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF Inhibition. Journal of Kidney Cancer and VHL, 2017, 4, 10-18.	0.2	3
80	Association of prior local therapy and outcomes with programmed cell death ligand-1 inhibitors in advanced urothelial cancer. BJU International, 2022, 130, 592-603.	1.3	3
81	Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer. Cancer Treatment and Research Communications, 2020, 24, 100193.	0.7	2
82	A Case Report with Severe Thrombocytopenia Induced by Axitinib. Case Reports in Hematology, 2020, 2020, 1-4.	0.3	2
83	Angiogenic and T-effector subgroups identified by gene expression profiling (GEP) and propensity for PBRM1 and BAP1 alterations in clear cell renal cell carcinoma (ccRCC).. Journal of Clinical Oncology, 2021, 39, 343-343.	0.8	2
84	PD-L1 Expression and Treatment Implications in Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review. Kidney Cancer, 2021, 5, 31-46.	0.2	2
85	Efficacy outcomes of nivolumab + cabozantinib versus pembrolizumab + axitinib in patients with advanced renal cell carcinoma (aRCC): Matching-adjusted indirect comparison (MAIC).. Journal of Clinical Oncology, 2021, 39, 4578-4578.	0.8	2
86	Circulating tumor (ct)-DNA alterations in urothelial/bladder cancer (UC/BC): Updates on a dynamic genomic landscape.. Journal of Clinical Oncology, 2017, 35, 4534-4534.	0.8	2
87	First-line PD-1/PD-L1 inhibitor monotherapy for advanced renal cell carcinoma (aRCC): A multi-institutional cohort.. Journal of Clinical Oncology, 2020, 38, e17109-e17109.	0.8	2
88	Outcomes and patterns of disease progression in metastatic renal cell carcinoma patients treated with nivolumab.. Journal of Clinical Oncology, 2018, 36, 654-654.	0.8	2
89	Systematic Review of Treatment of Metastatic Non-Clear Cell Renal Cell Carcinoma. Kidney Cancer, 2022, 6, 53-68.	0.2	2
90	Molecular alterations across sites of metastasis in patients with renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2022, 40, 287-287.	0.8	2

#	ARTICLE	IF	CITATIONS
91	Pathologic outcomes at cytoreductive nephrectomy (CN) following immunotherapy (IO) for patients with advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2022, 40, 334-334.	0.8	2
92	Comprehensive genomic profiling of penile squamous cell carcinoma and impact of HPV status on immune-checkpoint inhibition-related biomarkers.. Journal of Clinical Oncology, 2022, 40, 4-4.	0.8	2
93	SWOG S1931 (PROBE): Phase III randomized trial of immune checkpoint inhibitor (ICI) combination regimen with or without cytoreductive nephrectomy (CN) in advanced renal cancer.. Journal of Clinical Oncology, 2022, 40, TPS402-TPS402.	0.8	2
94	A systematic review of immune checkpoint inhibitors (ICI) in non-clear cell renal cell cancer (nccRCC) subtypes.. Journal of Clinical Oncology, 2022, 40, 353-353.	0.8	2
95	Repeat Treatment of Patients With Advanced Urothelial Carcinoma With Immune Checkpoint Inhibitors Following Prior Progression on a Checkpoint Inhibitor Regimen: A Case Series. Clinical Genitourinary Cancer, 2022, 20, 189-194.	0.9	2
96	A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer. Kidney Cancer, 2022, 6, 115-127.	0.2	2
97	Corticosteroid sensitivity in gliomatosis cerebri delays diagnosis. Practical Neurology, 2015, 15, 309-311.	0.5	1
98	The Costly War Against Cancer Treatment: The Example of Metastatic Renal Cell Carcinoma in Portugal. Acta Medica Portuguesa, 2018, 31, 373.	0.2	1
99	High-Dose Testosterone and Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2019, 17, 476-479.	0.9	1
100	Association of mTOR Pathway Markers and Clinical Outcomes in Patients with Intermediate-/High-risk Prostate Cancer: Long-Term Analysis. Clinical Genitourinary Cancer, 2019, 17, 366-372.	0.9	1
101	Skeletal-Related Events in Patients with Metastatic Renal Cell Carcinoma: A Systematic Review. Kidney Cancer, 2020, 4, 93-102.	0.2	1
102	Next Generation of Androgen Deprivation Therapy Combined With Radiotherapy for NO MO Prostate Cancer. Cancer Journal (Sudbury, Mass ), 2020, 26, 21-28.	1.0	1
103	PD-L1 inhibition with avelumab plus abiraterone acetate or enzalutamide in African Americans with metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, 87-87.	0.8	1
104	A dual drug therapy for sunitinib resistant RCC: An in vitro analysis.. Journal of Clinical Oncology, 2021, 39, 340-340.	0.8	1
105	Evaluation of cabozantinib (cabo) in combination with direct oral anticoagulants (DOAC) or low molecular weight heparin (LMWH) in renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2021, 39, 291-291.	0.8	1
106	Association of ATM mutations in metastatic prostate cancer with differential genomic alteration profiles from homologous recombination deficient and proficient tumors.. Journal of Clinical Oncology, 2021, 39, 5063-5063.	0.8	1
107	Differences in the tumor genomic landscape between African Americans (AA) and Caucasians (CA) advanced prostate cancer (aPC) patients (pts) by comprehensive genomic profiling (CGP) of cell-free DNA (cfDNA).. Journal of Clinical Oncology, 2021, 39, 5058-5058.	0.8	1
108	Real-world experience with atezolizumab (atezo) in advanced urothelial cancer (UC).. Journal of Clinical Oncology, 2017, 35, e16031-e16031.	0.8	1

#	ARTICLE	IF	CITATIONS
109	Pembrolizumab (pembro) in heavily pretreated metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2019, 37, 255-255.	0.8	1
110	First-line PD1/PD-L1 inhibitors for platinum-ineligible advanced urothelial carcinoma (UC).. Journal of Clinical Oncology, 2019, 37, 432-432.	0.8	1
111	Treatment patterns for metastatic hormone-sensitive prostate cancer (mHSPC) progressing after up-front docetaxel in combination with androgen deprivation therapy (D-ADT).. Journal of Clinical Oncology, 2018, 36, 305-305.	0.8	1
112	Association of circulating tumor (ct)-DNA genomic alterations (GA) with outcomes in metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2018, 36, 4540-4540.	0.8	1
113	Genomic changes of AR in ctDNA prior to enzalutamide in men with mCRPC after abiraterone acetate.. Journal of Clinical Oncology, 2019, 37, 320-320.	0.8	1
114	Outcomes of patients (pts) with metastatic urothelial cancer (mUC) and poor performance status (PS) receiving anti-PD(L)1 agents.. Journal of Clinical Oncology, 2019, 37, 4525-4525.	0.8	1
115	Considerations for the Attribution and Management of Toxicities in Phase I Clinical Trials. , 2020, , 109-118.		1
116	Treatment trends among men with metastatic castration sensitive prostate cancer (mCSPC): Results from the US component of an international study.. Journal of Clinical Oncology, 2022, 40, 66-66.	0.8	1
117	Blood-based tumor mutational burden from circulating tumor DNA and immune checkpoint inhibitors in advanced prostate cancer.. Journal of Clinical Oncology, 2022, 40, 165-165.	0.8	1
118	PATRIOT II: An ambispective, observational, multicenter, 2-cohort study of avelumab (Ave) first-line maintenance (1LM) in locally advanced/metastatic urothelial carcinoma (la/mUC) in the United States.. Journal of Clinical Oncology, 2022, 40, TPS578-TPS578.	0.8	1
119	Continuous IV Infusion of 5-Flourouracil in Heavily Pretreated Metastatic Castrate-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2022, 20, 586-590.	0.9	1
120	Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, TPS5107-TPS5107.	0.8	1
121	Tumores neuroendócrinos pancreáticos: análise retrospectiva de 12 anos de experiência do Instituto Português de Oncologia de Lisboa. Revista Portuguesa De Endocrinologia Diabetes E Metabolismo, 2013, 8, 2-8.	0.1	0
122	The Challenges of Implementing Multiarmed Early Phase Oncology Clinical Trials. , 2018, , 47-55.		0
123	Baseline pathogenic mutations in non-AR/non-TP53 genes and prediction of response to high-dose testosterone.. Journal of Clinical Oncology, 2021, 39, 146-146.	0.8	0
124	Real-world prevalence of homologous recombination repair gene (BRCA1/2 and ATM) mutations (HRRm) in patients (pts) with advanced prostate cancer (aPC) as detected by comprehensive genomic profiling (CGP) of circulating cell-free DNA (cfDNA).. Journal of Clinical Oncology, 2021, 39, 256-256.	0.8	0
125	Differences in the genomic landscape of advanced prostate cancer (aPC) patients (pts) with BRCA1 versus BRCA2 mutations as detected by machine learning analysis of the comprehensive genomic profile (CGP) of cell-free DNA (cfDNA).. Journal of Clinical Oncology, 2021, 39, 162-162.	0.8	0
126	Multi-institutional evaluation of the clinical outcomes and genomic correlates of African Americans with metastatic castration-sensitive prostate cancer (mCSPC).. Journal of Clinical Oncology, 2021, 39, 17-17.	0.8	0



#	ARTICLE	IF	CITATIONS
127	Landscape of circulating tumor DNA (ctDNA) abnormalities in advanced prostate cancer (aPCa): Distinctions in African American (AA) versus Caucasian (Ca) patients.. Journal of Clinical Oncology, 2021, 39, 156-156.	0.8	0
128	18F-fluciclovine positron emission tomography (PET) in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate.. Journal of Clinical Oncology, 2021, 39, TPS171-TPS171.	0.8	0
129	ctDNA pathogenic variants (PVs) in homologous recombination repair (HRR) genes in patients with metastatic CRPC.. Journal of Clinical Oncology, 2021, 39, 138-138.	0.8	0
130	Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients.. Journal of Clinical Oncology, 2021, 39, 143-143.	0.8	0
131	Treatment response in the intact primary renal mass (P-Rmass) and its relationship to the overall response to treatment in patients with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2021, 39, 329-329.	0.8	0
132	Volume matters and intensification is needed: emerging trends in the management of advanced prostate cancer. Drugs in Context, 2021, 10, 1-15.	1.0	0
133	Differential responses to taxanes and PARP inhibitors (PARPi) in <i>ATM</i> versus <i>BRCA2</i> -mutated metastatic castrate-resistant prostate cancer (mCRPC) patients (pts).. Journal of Clinical Oncology, 2021, 39, 5040-5040.	0.8	0
134	Immune checkpoint inhibitors (ICI) in advanced sarcomatoid renal cell carcinoma (sRCC): A multicenter study.. Journal of Clinical Oncology, 2021, 39, 4568-4568.	0.8	0
135	Cisplatin-based neoadjuvant chemotherapy (NAC) in bladder cancer patients (Pts) with borderline renal function: Implications for clinical practice.. Journal of Clinical Oncology, 2017, 35, 390-390.	0.8	0
136	Abstract A100: Seamless phase I/II clinical trials in oncology: retrospective analysis of the last 7 years. , 2018, , .		0
137	Atezolizumab (atezo) and subsequent therapies in patients (Pts) with metastatic urothelial carcinoma (mUC) outside clinical trials.. Journal of Clinical Oncology, 2018, 36, 432-432.	0.8	0
138	The association between HSD3B1 genotype and steroid metabolism in normal and prostate cancer (PCa) tissue.. Journal of Clinical Oncology, 2018, 36, TPS155-TPS155.	0.8	0
139	Response to platinum-based therapy (PBT) and immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts) with genomic alterations (GA) in homologous recombination repair (HRR) genes.. Journal of Clinical Oncology, 2018, 36, 447-447.	0.8	0
140	Cisplatin-based neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) in patients (pts) with impaired renal function.. Journal of Clinical Oncology, 2018, 36, 446-446.	0.8	0
141	The impact of switching systemic treatment after radiosurgery (SBRT) for oligo-progressive, metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2018, 36, 599-599.	0.8	0
142	Serial changes in PD1/PDL1 expression in metastatic urothelial carcinoma (mUC) patients (pts) treated with immune checkpoint blockade (CPB).. Journal of Clinical Oncology, 2018, 36, 109-109.	0.8	0
143	Tyrosine Kinase Inhibitors - Induced Cutaneous Leukocytoclastic Vasculitis. Gazeta MÃ©dica, 0, , 45-46.	0.0	0
144	Predictors of progressive disease (PD) and subsequent outcomes in metastatic renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo).. Journal of Clinical Oncology, 2018, 36, e16563-e16563.	0.8	0

#	ARTICLE	IF	CITATIONS
145	TP53 mutations in circulating tumor DNA in men with metastatic castration-resistant prostate cancer mCRPC.. Journal of Clinical Oncology, 2019, 37, 249-249.	0.8	0
146	First-line PD(L)1 inhibitors for platinum-ineligible advanced urothelial carcinoma (aUC).. Journal of Clinical Oncology, 2019, 37, e16024-e16024.	0.8	0
147	AR changes in circulating-tumor DNA (ctDNA) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with high-dose testosterone.. Journal of Clinical Oncology, 2019, 37, 5058-5058.	0.8	0
148	Development of Molecularly Targeted Agents in Early Phase Clinical Trials. , 2020, , 199-220.		0
149	EPID-03. SINGLE INSTITUTIONAL CLINICAL AND GENETIC ANALYSIS OF METASTATIC PROSTATE CANCER WITH AND WITHOUT BRAIN METASTASES. Neuro-Oncology, 2020, 22, ii78-ii79.	0.6	0
150	Comparative ctDNA analyses of African-American and Caucasian patients with CRPC.. Journal of Clinical Oncology, 2022, 40, 24-24.	0.8	0
151	Implications of androgen receptor (AR) alterations identified by genomic testing of tissue and blood from advanced prostate cancer (aPC) patients (pts).. Journal of Clinical Oncology, 2022, 40, 138-138.	0.8	0
152	DNA damaging therapies in patients (pts) with prostate cancer (PC) and pathogenic alterations in homologous recombination repair (HRR) genes.. Journal of Clinical Oncology, 2022, 40, 129-129.	0.8	0
153	Circulating tumor DNA responses to high-dose testosterone injections in CRPC patients.. Journal of Clinical Oncology, 2022, 40, 173-173.	0.8	0
154	Molecular and immune landscape of <i>FH</i>-mutated kidney cancer.. Journal of Clinical Oncology, 2022, 40, 382-382.	0.8	0
155	Impact of neoadjuvant immune checkpoint inhibitor therapy on primary tumor size and complexity: Correlation with surgical quality and short term oncological outcomes.. Journal of Clinical Oncology, 2022, 40, 390-390.	0.8	0
156	68ga-PSMA-11 patients with newly diagnosed and recurrent prostate cancer (Firefly).. Journal of Clinical Oncology, 2022, 40, TPS189-TPS189.	0.8	0
157	Longitudinal ctDNA alterations in germline positive CRPC patients.. Journal of Clinical Oncology, 2022, 40, 275-275.	0.8	0
158	Treatment (tx) patterns among men with metastatic castration resistant prostate cancer (mCRPC) in the United States (US).. Journal of Clinical Oncology, 2022, 40, 52-52.	0.8	0
159	Evaluation of ctDNA alterations in mCRPC patients with germline pathogenic mutations.. Journal of Clinical Oncology, 2022, 40, 177-177.	0.8	0
160	Phase 1 study of JNJ-69086420, an actinium-225-labeled antibody targeting human kallikrein-2, for advanced prostate cancer.. Journal of Clinical Oncology, 2022, 40, TPS5104-TPS5104.	0.8	0
161	Screening detects clinically significant hearing loss in patients with GU malignancies.. Journal of Clinical Oncology, 2022, 40, e18624-e18624.	0.8	0
162	Landscape analysis of urothelial carcinoma (UC) by telomerase reverse transcriptase (<i>TERT</i>) alterations.. Journal of Clinical Oncology, 2022, 40, 4524-4524.	0.8	0

#	ARTICLE	IF	CITATIONS
163	Molecular and immune landscape of <i>FH</i> -mutated cancers.. Journal of Clinical Oncology, 2022, 40, 3125-3125.	0.8	0
164	Activity of tivozanib in non-clear cell renal cell carcinoma (nccRCC): Subgroup analysis from a phase 2 randomized discontinuation trial.. Journal of Clinical Oncology, 2022, 40, 4542-4542.	0.8	0
165	Biomarker-directed therapy in black and white men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, 5013-5013.	0.8	0